Gene Map

TBK1-Map from Weekly BioAnalysis, October 2011

TBK1 was selected from the news on July 14, 2011 for Weekly Bio Analysis. The news says TBK1 is a good pharmacological intervention target for a subset of lung and pancreas cancers. So we thought that finding some candidates for TBK1-downregulating compounds can be very meaningful.

Analysis Scheme

First, we searched for known drugs or compounds that downregulate TBK1. According to Gene Map, there is no known drug but some compounds have downregulating activities.

20110919_img1.jpg
Gene-Map of "TBK-1"
20110919_img2.jpg
Ethinyl Estradiol, Luteolin, Resveratrol, Tetrachlorodibenzodioxin, Acetaminophen, etc...

Next, we focused on PCI validation for determining possible candidates. PCI validation shows a protein-chemical interaction pair with their PDB-Ligand pair as evidence.

20110919_img3.jpg

13 compounds were found in PCI validation, and five of them have their pharmacological action known, so it is possible that they are drug repositioning candidates.

20110919_img4.jpg

It is possible that the rest of the eight compounds whose pharmacological actions are not known become brand new drugs, and one can test if they can actually bind to TBK1 using a 3D simulation.

eg. tanimoto coeffitient between (R,S)-Roscovitine and ligand P01 is 0.674

20110919_img5.jpg
P01
20110919_img6.jpg
(R,S)-Roscovitine
20110919_img7.jpg
Overlapping
20110919_img8.jpg
Docking
Source Institution: UT Southwestern Medical Center
Source Author: Ou YH et al.
Original Link: